Treatment Of Acne Rosacea With Pancreatic Lipase-Related Protein 3 (PNLIPRP3) Inhibitors
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsAntoine Baldassari, William Palmer, Katherine Siminovitch, Manuel Ferreira, Priyanka Nakka, Aris Baras
Life of this patent
Estimating the term…
Abstract
The present disclosure generally relates to the treatment of subjects having acne rosacea or at risk of developing acne rosacea by administering a Pancreatic Lipase-Related Protein 3 (PNLIPRP3) inhibitor to the subject.
Claims22
A method of treating a subject having acne rosacea or at risk of developing acne rosacea, the method comprising administering a Pancreatic Lipase-Related Protein 3 (PNLIPRP3) inhibitor to the subject.
A method of treating a subject having acne rosacea or at risk of developing acne rosacea by administering an acne rosacea therapeutic agent or acne rosacea therapy, the method comprising:
- determining or having determined whether the subject has a Pancreatic Lipase-Related Protein 3 (PNLIPRP3) variant nucleic acid molecule, by:
- obtaining or having obtained a biological sample from the subject;
- and
- performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising a PNLIPRP3 variant nucleic acid molecule;
- and
- administering or continuing to administer the acne rosacea therapeutic agent in an amount that is the same as or less than a standard dosage amount or acne rosacea therapy, and/or a PNLIPRP3 inhibitor to a subject that is PNLIPRP3 reference;
- administering or continuing to administer the acne rosacea therapeutic agent in an amount that is the same as or less than a standard dosage amount or acne rosacea therapy, and/or a PNLIPRP3 inhibitor to a subject that is heterozygous for the PNLIPRP3 variant nucleic acid molecule;
- or
- administering or continuing to administer the acne rosacea therapeutic agent in a standard dosage amount or acne rosacea therapy to a subject that is homozygous for the PNLIPRP3 variant nucleic acid molecule;
- wherein the presence of the PNLIPRP3 variant nucleic acid molecule indicates the subject has a decreased risk of developing acne rosacea.
(canceled)
A method of identifying a subject having an increased risk of developing acne rosacea, the method comprising:
- determining or having determined the presence or absence of a PNLIPRP3 variant nucleic acid molecule in a biological sample obtained from the subject;
- wherein:
- when the subject is PNLIPRP3 reference, then the subject has an increased risk of developing acne rosacea;
- and
- when the subject is heterozygous or homozygous for the PNLIPRP3 variant nucleic acid molecule, then the subject has a decreased risk of developing acne rosacea.
22-41. (canceled)
Dependencies are inferred from the claim text.